1-for-20 reverse split consolidates Quince Therapeutics (NASDAQ: QNCX) shares
Rhea-AI Filing Summary
Quince Therapeutics, Inc. approved and implemented a 1-for-20 reverse stock split of its common stock. The company filed a Certificate of Amendment in Delaware effective at 11:59 p.m. Eastern Time on June 29, 2026, and its shares will begin trading on a split-adjusted basis on June 30, 2026.
Every twenty shares of issued and outstanding common stock will be combined into one share, leaving stockholder ownership percentages generally unchanged, except that fractional shares will be settled in cash. Shares outstanding will decline from 19,559,257 immediately before the split to approximately 977,963 after the split. The stock will continue trading under the symbol QNCX with a new CUSIP number 22053A305.
Positive
- None.
Negative
- None.
Insights
Quince executes a 1-for-20 reverse split, consolidating shares without changing ownership stakes.
The reverse stock split combines every twenty existing shares of Quince Therapeutics common stock into one new share, reducing the count from 19,559,257 to about 977,963. This is a capital-structure change; it does not alter total company value by itself.
The company states that stockholder percentage ownership remains generally the same, with cash payments instead of fractional shares. All outstanding stock options and warrants are proportionally adjusted, and the stock will trade split-adjusted on the Nasdaq Global Select Market from June 30, 2026 with a new CUSIP.
8-K Event Classification
3 items: 3.03, 5.03, 9.01
3 items
Item 3.03
Material Modification to Rights of Security Holders
Securities
A change was made that materially affects the rights of existing shareholders (e.g., dividend rights, voting rights).
Item 5.03
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Governance
The company amended its charter documents, bylaws, or changed its fiscal year.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Reverse split ratio: 1-for-20
Shares outstanding before split: 19,559,257 shares
Shares outstanding after split: Approximately 977,963 shares
+3 more
6 metrics
Reverse split ratio
1-for-20
Approved by board for common stock
Shares outstanding before split
19,559,257 shares
Immediately prior to reverse stock split
Shares outstanding after split
Approximately 977,963 shares
Immediately after reverse stock split becomes effective
Effective time
11:59 p.m. Eastern Time
Reverse split effective on June 29, 2026
Split-adjusted trading start
June 30, 2026
Nasdaq Global Select Market, symbol QNCX
New CUSIP
22053A305
Common stock post reverse split
Key Terms
Reverse Stock Split, Certificate of Amendment, CUSIP, transfer agent, +1 more
5 terms
Reverse Stock Split financial
"the Company’s stockholders approved the implementation of a reverse stock split"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
Certificate of Amendment regulatory
"a form of certificate of amendment to the Company’s Amended and Restated Certificate of Incorporation"
A certificate of amendment is an official filing that updates a company’s founding documents—its legal “rulebook” that sets share structure, voting rules, name and basic purpose. Think of it like changing the blueprint of a building: small changes are paperwork, big ones can alter who owns how much and who controls decisions. Investors watch these filings because they can affect share counts, voting power, dilution and company value.
CUSIP financial
"The common shares will trade under a new CUSIP number, 22053A305"
A CUSIP is a nine-character alphanumeric code that uniquely identifies a U.S. or Canadian financial security—such as a stock, bond, or fund share—like a Social Security number for an investment. It matters to investors because brokers, exchanges and record-keepers use the CUSIP to match trades, track ownership, settle transactions and pull accurate records, reducing errors and ensuring money and securities go to the right place.
transfer agent financial
"The Company has appointed its transfer agent, Equiniti Trust Company, LLC, to act as exchange agent"
A transfer agent is a financial service that keeps the official record of who owns a company's shares, handles the buying and selling of those shares on paper or electronically, and issues or cancels stock certificates. Think of it as the company’s records keeper and mailroom combined—investors rely on it to make sure dividends, shareholder mailings, ownership changes, and proxy voting are processed accurately and securely, which protects ownership rights and helps prevent errors or fraud.
Nasdaq Global Select Market market
"will begin trading on a split-adjusted basis on the Nasdaq Global Select Market"
A Nasdaq Global Select Market listing is the highest tier of stocks on the Nasdaq exchange, reserved for companies that meet the strictest financial, reporting and governance standards. For investors, it acts like a premium quality label—signaling larger, more transparent and better-governed companies that tend to offer greater liquidity and lower perceived risk compared with lower-tier listings, making it easier to buy, sell and evaluate shares.
FAQ
What corporate action did Quince Therapeutics (QNCX) disclose in this 8-K?
Quince Therapeutics disclosed a 1-for-20 reverse stock split of its common stock. The split is implemented through a Certificate of Amendment and consolidates existing shares into a smaller number without generally changing each stockholder’s percentage ownership, aside from cash payments for fractional shares.
What is the ratio and effect of Quince Therapeutics’ reverse stock split?
The reverse stock split uses a 1-for-20 ratio, combining every twenty existing shares into one new share. Immediately before the split there were 19,559,257 shares outstanding, and afterward there will be approximately 977,963 shares outstanding, while overall ownership percentages remain largely unchanged.
When will Quince Therapeutics’ reverse split become effective and start trading?
The reverse stock split becomes effective at 11:59 p.m. Eastern Time on June 29, 2026. Quince Therapeutics’ common stock will begin trading on a split-adjusted basis on the Nasdaq Global Select Market when markets open on June 30, 2026, under the same ticker symbol QNCX.
Will Quince Therapeutics’ reverse stock split change stockholder rights or ticker symbol?
The company states the reverse stock split will not modify the rights or preferences of its common stock. Quince’s shares will continue trading under the symbol QNCX, but will have a new CUSIP number 22053A305 once trading begins on a split-adjusted basis on June 30, 2026.
How are Quince Therapeutics’ options and warrants affected by the reverse split?
All stock options and warrants outstanding immediately before the reverse split are proportionally adjusted to reflect the 1-for-20 ratio. This keeps the economic value of these instruments aligned with the post-split share count while preserving their underlying contractual terms as adjusted.
AI-generated analysis. How Rhea-AI works. Not financial advice.
